loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Rubicon Research Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Rubicon Research Ltd. 01 Jun 2026 12:33 PM

Q4FY26 & FY26 Result Announced for Rubicon Research Ltd.

Pharmaceuticals company Rubicon Research announced Q4FY26 & FY26 results

Q4FY26 Consolidated Financial Highlights:

  • Revenue from Operations: Stood at Rs 5,139.15 million in Q4FY26, registering a strong YoY growth of 43.49% compared to Rs 3,581.47 million in Q4FY25, and a QoQ growth of 8.07% compared to Rs 4,755.29 million in Q3FY26.
  • Total Income: Reached Rs 5,165.25 million, showcasing a YoY increase of 44.18% (from Rs 3,582.45 million in Q4FY25) and a QoQ increase of 7.76% (from Rs 4,793.16 million in Q3FY26).
  • Profit Before Tax (PBT): Reported at Rs 986.87 million, up by 93.28% YoY from Rs 510.60 million in Q4FY25, and higher by 8.94% QoQ from Rs 905.86 million in Q3FY26.
  • Net Profit After Tax (PAT): Stood at Rs 767.85 million, reflecting a massive YoY growth of 111.85% compared to Rs 362.45 million in Q4FY25, and a QoQ growth of 5.48% from Rs 727.97 million in Q3FY26.

FY26 Consolidated Financial Highlights:

  • Revenue from Operations: Grew by 36.57% YoY to Rs 17,539.56 million in FY26, compared to Rs 12,842.72 million in FY25.
  • Total Income: Increased by 36.79% YoY to Rs 17,616.83 million, up from Rs 12,879.06 million in the previous financial year.
  • Profit Before Tax (PBT): Stood at Rs 3,205.34 million, marking a 64.78% growth over Rs 1,945.23 million reported in FY25.
  • Net Profit After Tax (PAT): Achieved a robust growth of 83.64% YoY, rising to Rs 2,467.35 million in FY26 from Rs 1,343.61 million in FY25.

Q4FY26 Standalone Financial Highlights:

  • Revenue from Operations: Reached Rs 3,898.78 million, increasing by 29.61% YoY (vs Rs 3,008.06 million in Q4FY25) and 29.22% QoQ (vs Rs 3,017.11 million in Q3FY26).
  • Total Income: Stood at Rs 3,934.59 million, up by 25.80% YoY (vs Rs 3,127.75 million in Q4FY25) and 28.58% QoQ (vs Rs 3,060.12 million in Q3FY26).
  • Profit Before Tax (PBT): Reported at Rs 941.85 million, up 74.64% YoY (vs Rs 539.31 million in Q4FY25) and 90.17% QoQ (vs Rs 495.28 million in Q3FY26).
  • Net Profit After Tax (PAT): Stood at Rs 700.20 million, displaying a YoY growth of 73.89% (vs Rs 402.67 million in Q4FY25) and a QoQ growth of 88.32% (vs Rs 371.81 million in Q3FY26).

FY26 Standalone Financial Highlights:

  • Revenue from Operations: Grew to Rs 13,060.82 million, a rise of 21.63% from Rs 10,738.43 million in FY25.
  • Total Income: Amounted to Rs 13,169.14 million, increasing by 20.43% from Rs 10,935.24 million in FY25.
  • Profit Before Tax (PBT): Stood at Rs 2,527.79 million, marking a 13.21% YoY increase over Rs 2,232.80 million in FY25.
  • Net Profit After Tax (PAT): Reported at Rs 1,881.65 million, registering a 12.31% YoY growth from Rs 1,675.37 million in FY25.

Business Highlights:

  • Segment-wise Performance: The company is primarily engaged in a single business segment, which is the "Sale of Pharmaceuticals products". Therefore, there are no other reportable operating segments.
  • Dividend Announcement: The Board of Directors recommended a final dividend of Rs 1.50 per equity share of the face value of Rs 1 each for the financial year ended March 31, 2026.
  • Initial Public Offering (IPO) & Listing: During FY26, the company successfully completed its IPO aggregating to Rs 13,775.00 million. This comprised a fresh issue of Rs 5,000.00 million and an Offer for Sale (OFS) of Rs 8,775.00 million. The equity shares were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on October 16, 2025. Consequently, General Atlantic Singapore RR PTE Ltd is no longer a holding company.
  • International Expansion: The company incorporated a wholly-owned subsidiary, AdvaGen S A Company, in the Kingdom of Saudi Arabia on January 13, 2026, to engage in the trading of finished pharmaceutical products.
  • Strategic Acquisition: The company entered into a definitive agreement to acquire a 65% stake in Arnna Lifesciences Limited for a total consideration of Rs 1,759.17 million. The acquisition was successfully completed post the financial year end, on April 30, 2026.
  • Regulatory Update: The Goods and Services Tax (GST) authorities conducted an inspection at the company's premises located in Thane and Ambernath on January 30, 2026. The company extended full cooperation, and based on the assessment performed, no material discrepancies requiring adjustment in the financial results were identified, nor was any show-cause notice or order received.

Result PDF

Pharmaceuticals company Rubicon Research announced Q3FY26 results

  • Revenue: Rs 4,755 million against Rs 3,134 million during Q3FY25, change 52%.
  • EBITDA: Rs 1,119 million against Rs 704 million during Q3FY25, change 59%.
  • EBITDA Margin: 23.5% for Q3FY26.
  • PBT: Rs 906 million against Rs 532 million during Q3FY25, change 70%.
  • PAT: Rs 728 million against Rs 381 million during Q3FY25, change 91%.
  • EPS: Rs 4.41 for Q3FY26.

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app